NCCN Releases New Patient-Centered Guideline for NETs
The National Comprehensive Cancer Network (NCCN) published a new resource that offers patients and clinicians up-to-date information on neuroendocrine tumors (NETs).
"It is imperative to have access to the best and most accurate information when coming up with a treatment plan,” said Maryann Wahmann, patient and founder, Neuroendocrine Cancer Awareness Network (NCAN), a sponsor of the guideline. “The NCCN Guidelines for Patients: NET is an amazing resource for patients and caregivers, helping them become their best self-advocate."
The most common types of NETs are carcinoid tumors in the lung, airways, small intestine, rectum, appendix, thymus, and pancreas. NETs are known to cause hormones to be released into the blood system.
The guideline consists of evidence and expert-consensus available in the clinical practice guidelines created by NCCN’s multidisciplinary panels from 27 academic cancer centers in the US. Treatment recommendations are designed to be user-friendly – complete with glossaries, illustrations, and ample space for note-taking.
The NCCN Guidelines for Patients: NET is organized into eight parts.
- Background information on NETs
- Testing and diagnostics
- Overview of available treatments
- Guide for treating NETs of the gastrointestinal tract
- Guide for treating NETs of the thymus, lungs, and bronchi
- Guide for treating NETs of the pancreas
- Guide for treating other NETs
- Tips for making optimal treatment decisions
“It really takes a multidisciplinary team to treat these tumors,” explained Whitney S Goldner, MD, Fred & Pamela Buffet Cancer Center (Omaha, NE), in a press release (October 9, 2018). “Everybody plays a different role in the care of NETs, including endocrinologists, medical oncologists, surgical oncologists, radiation oncologists, and sometimes nuclear medicine radiologists. These guidelines help prepare patients for the group of people who will comprise their treatment team, and ensure they understand the need for specific testing and therapies for their tumor.”
The guideline was funded by the NCCN Foundation, with sponsorship from NCAN and The Healing NET Foundation. The Carcinoid Cancer Foundation, Inc and the Neuroendocrine Tumor Research Foundation also endorsed the guideline.—Zachary Bessette